Legal Representation
Attorney
Alisa C. Simmons
USPTO Deadlines
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 28, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 5, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Nov 5, 2024 | EXT4 | S | SOU EXTENSION 4 FILED |
| Nov 5, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 19, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 18, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Apr 18, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 18, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 1, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 30, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Oct 30, 2023 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 30, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 5, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
| May 5, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
| May 5, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 8, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sep 13, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 13, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 24, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 5, 2022 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Aug 5, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 21, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 21, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 21, 2022 | ALIE | A | ASSIGNED TO LIE |
| Jul 6, 2022 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
| Jul 6, 2022 | PETG | O | PETITION TO REVIVE-GRANTED |
| Jul 6, 2022 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Jul 6, 2022 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Jul 1, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 1, 2022 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
| Dec 23, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Dec 23, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Dec 23, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Dec 10, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 9, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Dec 9, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jun 9, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 9, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Jun 9, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jun 8, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jun 8, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 8, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Dec 9, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Dec 9, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Dec 9, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Dec 3, 2020 | DOCK | D | ASSIGNED TO EXAMINER |
| Sep 10, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 13, 2020 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceuticals, namely, pharmaceutical preparations for repair of organs damaged by trauma, burns, drugs, radiation, hypoxia, and explosive device; pharmaceuticals, namely, pharmaceutical preparations for reversing effects of aging; pharmaceutical preparations for the prevention and treatment of autoimmune diseases or disorders; pharmaceutical preparations for treating degenerative diseases and disorders of joints, heart, cardiovascular system, brain, spinal cord, ligaments, muscles, kidneys, liver, skin and lungs; pharmaceutical preparations for treatment of connective tissue diseases and disorders; pharmaceutical preparations for the treatment of musculoskeletal related diseases and disorders; pharmaceutical preparations for the prevention and treatment of vascular diseases or disorders; pharmaceutical preparations for the treatment of cardiovascular related diseases or disorders; pharmaceutical preparations for the treatment of neurological disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for treatment of cardiopulmonary and pulmonary related diseases and disorders; pharmaceutical preparations for use in skin care; astringents for medicinal purposes; pharmaceutical skin lotions; stem cells for medical purposes
Additional Information
Pseudo Mark
MAE CELL
Classification
International Classes
005